OPKO HealthLTS:0KCS +3.36%53 Days Payable is 49.60 as of Mar. 2026, which is 32% above its 10-year median of 37.57. GuruFocus rates LTS:0KCS with a GF Score™ of 53/100 and a GF Value™ of $1.07 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 190 Medical Diagnostics & Research companies, OPKO Health ranks worse than 61.05% on this metric.
The historical rank and industry rank for OPKO Health's Days Payable or its related term are showing as below:
LTS:0KCS'
s Days Payable Range Over the Past 10 Years
Min: 27.98 Med: 37.57 Max: 49.48
Current: 49.48
During the past 13 years, OPKO Health's highest Days Payable was 49.48. The lowest was 27.98. And the median was 37.57.
LTS:0KCS's Days Payable is ranked worse than 61.05% of 190
companies
in the Medical Diagnostics & Research industry
Industry Median: 67.275
vs LTS:0KCS: 49.48
OPKO Health's Days Payable
increased
from Mar. 2025 (45.25) to Mar. 2026 (49.60).
It may suggest that OPKO Healthdelayed paying its suppliers.
OPKO Health Days Payable Related Terms
OPKO Health Days Payable Historical Data
* Premium members only.
The historical data trend for OPKO Health's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0KCS vs PSNL, CDNA, CSTL: Days Payable Comparison
For the Diagnostics & Research subindustry, OPKO Health's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OPKO Health Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, OPKO Health's Days Payable distribution charts can be found below:
* The bar in red indicates where OPKO Health's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
OPKO Health's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OPKO Health (LTS:0KCS) has a Days Payable of 49.60 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on OPKO Health and its competitors. This is 32% above median its historical median of 37.57. Over the past decade, OPKO Health's Days Payable has ranged from 27.98 to 49.48. According to the industry distribution chart, OPKO Health ranks #116 out of 190 companies in the Medical Diagnostics & Research industry, placing it in the top 61.1%.
Is OPKO Health's Days Payable too high?
OPKO Health's current Days Payable of 49.60 is 32% above median its 10-year median of 37.57. Over the past 10 years, this metric has ranged from a low of 27.98 to a high of 49.48. The Medical Diagnostics & Research industry median Days Payable is 67.28. OPKO Health's value of 49.60 is 26.3% below this industry median. Based on the distribution chart, OPKO Health ranks #116 out of 190 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, OPKO Health has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does OPKO Health's Days Payable compare to PSNL and CDNA?
According to the Medical Diagnostics & Research industry distribution chart, OPKO Health ranks #116 out of 190 companies for Days Payable. This places OPKO Health in the lower half of its industry. The industry median Days Payable is 67.28. OPKO Health's value of 49.60 is 26.3% below this benchmark. Historically, OPKO Health's own Days Payable has ranged from 27.98 to 49.48 over the past decade. While the company's 10-year median is 37.57 vs. the industry median of 67.28, OPKO Health has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 67.28, based on 190 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. OPKO Health's current Days Payable of 49.60 is 26.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on OPKO Health and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 67.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OPKO Health's current Days Payable is 49.60, which is 32% above median its own 10-year median of 37.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OPKO Health stock overvalued right now?
Based on GuruFocus' analysis, OPKO Health (LTS:0KCS) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.07, compared to a current price of $1.54 — trading 43.9% above its estimated fair value. The current Days Payable is 49.60, which is 32% above median its 10-year median of 37.57 and 26.3% below the Medical Diagnostics & Research industry median of 67.28. OPKO Health's overall GF Score™ is 53/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For OPKO Health (LTS:0KCS), the current Days Payable is 49.60 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is OPKO Health (LTS:0KCS) Overvalued in 2026?
Based on GuruFocus' analysis, OPKO Health stock appears to be overvalued.
The current stock price of $1.54 is trading 43.9% above its estimated GF Value™ of $1.07.
GuruFocus considers OPKO Health to be Significantly Overvalued.
Key valuation signals for LTS:0KCS:
Days Payable: 49.60 (32% above median its 10-year median of 37.57)
GF Value™: $1.07 vs. price of $1.54 (43.9% above fair value)
Industry Position: 26.3% below the Medical Diagnostics & Research median (#116 of 190)
No single metric tells the full story. See the LTS:0KCS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.
53GF Score
Get the complete analysis for LTS:0KCS
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0KCS has been successfully added to your 
